It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx ... receive nerve signals from different parts of the body. Those chemical interactions also give rise ...

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including ...

Vertex Pharma has made its name ... The therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose.

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...